- Home
- NGG vs ALNY Comparison
NGG vs ALNY Comparison
Compare NGG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGG
- ALNY
- Stock Information
- Founded
- NGG 1990
- ALNY 2002
- Country
- NGG United Kingdom
- ALNY United States
- Employees
- NGG N/A
- ALNY N/A
- Industry
- NGG Natural Gas Distribution
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- NGG Utilities
- ALNY Health Care
- Exchange
- NGG Nasdaq
- ALNY Nasdaq
- Market Cap
- NGG 72.3B
- ALNY 59.6B
- IPO Year
- NGG 1999
- ALNY 2004
- Fundamental
- Price
- NGG $73.93
- ALNY $458.59
- Analyst Decision
- NGG Hold
- ALNY Strong Buy
- Analyst Count
- NGG 2
- ALNY 29
- Target Price
- NGG N/A
- ALNY $448.97
- AVG Volume (30 Days)
- NGG 568.2K
- ALNY 1.0M
- Earning Date
- NGG 11-06-2025
- ALNY 10-30-2025
- Dividend Yield
- NGG 4.12%
- ALNY N/A
- EPS Growth
- NGG N/A
- ALNY N/A
- EPS
- NGG 0.79
- ALNY N/A
- Revenue
- NGG $23,744,492,829.00
- ALNY $2,461,963,000.00
- Revenue This Year
- NGG $0.45
- ALNY $59.55
- Revenue Next Year
- NGG $10.16
- ALNY $40.90
- P/E Ratio
- NGG $93.17
- ALNY N/A
- Revenue Growth
- NGG N/A
- ALNY 5.01
- 52 Week Low
- NGG $55.82
- ALNY $205.87
- 52 Week High
- NGG $74.82
- ALNY $484.21
- Technical
- Relative Strength Index (RSI)
- NGG 65.93
- ALNY 58.80
- Support Level
- NGG $71.94
- ALNY $446.18
- Resistance Level
- NGG $73.62
- ALNY $465.01
- Average True Range (ATR)
- NGG 0.77
- ALNY 11.41
- MACD
- NGG 0.33
- ALNY -2.05
- Stochastic Oscillator
- NGG 89.04
- ALNY 65.04
About NGG National Grid Transco PLC National Grid PLC (NEW)
National Grid owns and operates the electric transmission system in England and Wales. It sold the bulk of its UK gas transmission business in fiscal 2023 to fund the acquisition of PPL's UK power distribution assets. In the Northeastern United States, it serves electricity and gas customers combined in three states. It also owns regulated transmission and electricity generation in the United States, metering services, merchant transmission lines in the UK, and the Grain (UK) liquefied natural gas facility.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.